NCT01858181View on ClinicalTrials.gov

Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies

PHASE1UnknownINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Conditions
Previously Treated CD20+ B-cell Malignancies
Interventions
BIOLOGICAL

ocaratuzumab

Trial Locations (1)

75390

Universtity of Texas Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Mentrik Biotech, LLC

INDUSTRY